Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

Peer Review reports

Original Submission
23 Aug 2018	Submitted	Original manuscript
31 Aug 2018	Author responded	Author comments - Iben Kümler
Resubmission - Version 2
31 Aug 2018	Submitted	Manuscript version 2
14 Nov 2018	Reviewed	Reviewer Report - Reham Abdel-Wahab
13 Apr 2019	Reviewed	Reviewer Report - Peter Kern
13 May 2019	Author responded	Author comments - Iben Kümler
Resubmission - Version 3
13 May 2019	Submitted	Manuscript version 3
Publishing
31 May 2019	Editorially accepted
13 Jun 2019	Article published	10.1186/s12885-019-5788-9

Back to article page